Distinguishing Dementia with Lewy Bodies from Alzheimer Disease: What is the Influence of the GBA Genotype in Ashkenazi Jews?

Noa Bregman, Gitit Kavé, Anat Mirelman, Avner Thaler, Mali Gana Weisz, Anat Bar-Shira, Avi Orr-Urtreger, Nir Giladi, Tamara Shiner

Research output: Contribution to journalArticlepeer-review


Cognitive deficits beyond memory impairment, such as those affecting language production or executive functioning, can be useful in clinically distinguishing between dementia syndromes. We tested the hypothesis that Ashkenazi Jewish (AJ) patients who have dementia with Lewy bodies (DLB) and carry glucocerebrosidase (GBA) mutations will have verbal fluency deficits different from those found in Alzheimer disease (AD), whereas AJ patients with DLB who have no GBA mutations will have similar deficits in verbal fluency to those found in AD. We compared performance in phonemic and semantic verbal fluency tasks in 44 AJ patients with DLB and 20 patients with AD, matched for age, education, and age of immigration. All groups were found to have a deficit in semantic verbal fluency. On conducting the phonemic task, patients with DLB who carried GBA mutations scored more poorly than patients with AD, whereas DLB-noncarriers performed similarly to patients with AD. We suggest that verbal fluency tasks could serve as a possible clinical marker to subtype patients with DLB, with phonemic fluency being a marker for GBA-associated DLB.

Original languageEnglish
Pages (from-to)279-281
Number of pages3
JournalAlzheimer Disease and Associated Disorders
Issue number3
StatePublished - 2019

Bibliographical note

Funding Information:
N.G. reports serving as a member of the editorial board for the Journal of Parkinson’s Disease; serving as a consultant to Teva-Lundbeck, IntecPharma, NeuroDerm, Armon Neuromedical Ltd, Dexel, Mon-fort, and Lysosomal Therapeutic Inc.; receiving payment for lectures at Teva-Lundbeck, Novartis, UCB, AbbVie, Shaier, and Genzyme; and receiving research support from the Michael J. Fox Foundation, the National Parkinson Foundation, the European Union Seventh Framework Program, the Israel Science Foundation, Teva NNE program, LTI, AbbVie, and CHDI. The remaining authors declare no conflicts of interest.

Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.


  • Alzheimer disease
  • cognitive evaluation
  • dementia with Lewy bodies
  • glucocerobrosidase mutations
  • verbal fluency


Dive into the research topics of 'Distinguishing Dementia with Lewy Bodies from Alzheimer Disease: What is the Influence of the GBA Genotype in Ashkenazi Jews?'. Together they form a unique fingerprint.

Cite this